Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $40.13.

A number of analysts have issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Finally, Stephens initiated coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target for the company.

Bicycle Therapeutics Trading Down 2.9 %

NASDAQ:BCYC opened at $19.95 on Thursday. The business’s fifty day moving average price is $23.97 and its 200 day moving average price is $23.03. The firm has a market capitalization of $948.62 million, a price-to-earnings ratio of -6.35 and a beta of 0.89. Bicycle Therapeutics has a 1-year low of $13.31 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period last year, the company earned ($1.26) earnings per share. Equities analysts forecast that Bicycle Therapeutics will post -3.07 earnings per share for the current year.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,212 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the sale, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,840 shares of company stock worth $259,128 in the last 90 days. 8.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BCYC. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter worth approximately $34,000. GAMMA Investing LLC increased its stake in shares of Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after buying an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the last quarter. XTX Topco Ltd bought a new stake in Bicycle Therapeutics during the 2nd quarter worth about $206,000. Finally, Crossmark Global Holdings Inc. acquired a new position in Bicycle Therapeutics in the third quarter valued at approximately $257,000. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.